Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-18Clinical Trial Update: Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
A real-world pharmacological monitoring study of the encorafenib and binimetinib combination for metastatic melanoma is currently recruiting…
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1]
Phase 1 trial evaluating SL-279252, a PD-1-Fc-OX40L fusion protein, in adults with advanced solid tumors or lymphomas has been completed wit…
-
CLINICAL_TRIALS trial_result · 2025-03-13Clinical Trial Update: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination or sequencing of vemurafenib, cobimetinib, and atezolizumab in patients with high-ris…
-
CLINICAL_TRIALS trial_result · 2025-03-13Clinical Trial Update: Study of INCB086550 in Select Solid Tumors [Phase 2]
A Phase 2 trial evaluating INCB086550 across select solid tumors, including non-small cell lung cancer and urothelial carcinoma, was termina…
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease [Phase 2]
A Phase 2 trial evaluating the neo-adjuvant combination of talimogene laherparepvec (T-VEC) and nivolumab for resectable stage III/IV melano…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients
A completed clinical trial update studying BRAF and MEK inhibition with dabrafenib and trametinib in melanoma patients.
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR) [EARLY_Phase 1]
Phase I/II study of Fragmented Autoantigen Stimulated T-cell-immunotherapy (FAST-CR) combined with radiotherapy. The trial targets breast ca…
-
CLINICAL_TRIALS research · 2025-03-11Clinical Trial Update: In Vivo Liquid Biopsy of Melanoma (Cytophone) [NA]
Registration indicates a Cytophone-based in vivo liquid biopsy trial for melanoma evaluating circulating tumor cells, including metastatic m…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma [Phase 1, Phase 2]
A multicenter Phase 1b/2 neoadjuvant trial evaluating the combination of domatinostat, nivolumab, and ipilimumab in stage III cutaneous or u…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma [Phase 3]
Phase III study comparing tumor-infiltrating lymphocytes (TIL) therapy to ipilimumab in metastatic melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors [Phase 2]
Phase 2 trial of ladiratuzumab vedotin in multiple advanced solid tumors was terminated, with results posted in March 2025.
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: FMT to Convert Response to Immunotherapy [Phase 1, Phase 2]
A Phase 1/2 clinical trial at The Netherlands Cancer Institute is evaluating fecal microbiota transplant to convert response to immunotherap…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) [Phase 2]
Phase 2 clinical trial update on pixatimod (PG545) plus nivolumab in PD-1 relapsed/refractory metastatic melanoma and non-small cell lung ca…
-
FDA approval · 2025-03-07FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA supplemental application for TAFINLAR (dabrafenib) submitted by Novartis Pharmaceuticals Corporation to seek changes to the drug's label…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) [Phase 1, Phase 2]
Phase 1b and Phase 2 NAUTILUS trial evaluating OKI-179 plus binimetinib in NRAS-mutated melanoma and other RAS-pathway–altered solid tumors …
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: ATL001 in Patients With Metastatic or Recurrent Melanoma [Phase 1, Phase 2]
The ATL001 trial in metastatic or recurrent melanoma (Phase 1/2) has been terminated, and results have been posted.
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
A clinical trial update exploring the use of circulating tumor DNA (ctDNA) to detect melanoma recurrence earlier than current methods.
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
This clinical trial update describes an ongoing study evaluating circulating tumor cells and microRNAs in patients with metastatic melanoma,…
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
ClinicalTrials.gov update reports completion and results posting of a comparative effectiveness study evaluating targeted therapies for BRAF…
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: MGD019 DART® Protein in Unresectable/Metastatic Cancer [Phase 1]
MGD019, a DART protein from MacroGenics, is being studied in a Phase 1 trial for unresectable/metastatic cancers, including non-small cell l…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail Apparatus for Melanoma
A review of the literature and a case series of patients who underwent reconstruction after wide local excision of nail apparatus melanoma.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
A completed multicancer registry study (PREFER) assessing the prevalence of actionable biomarkers and driver mutations across advanced cance…
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating Fluzoparib in combination with Camrelizumab and Temozolomide for advanced melanoma and is currently…
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases [NA]
Clinical trial update describing a study investigating precision radiation for metastatic melanoma that has become resistant to immune check…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy
The study update reports observations of taste and smell dysfunction occurring more than two years after initiation of immune checkpoint inh…